skip to Main Content

2023 Statements

The 1/4/6×24 Campaign Coalition Welcomes India’s Rejection of Johnson & Johnson’s Patent Evergreening Tactic
March 28, 2023 — The Indian Patent Office has taken a laudable step that will pave the way for generic manufacturing of a key tuberculosis (TB) drug.

For World TB Day, TB Advocates Demand Universal Access to Shorter, Safer TB Regimens
March 20, 2023 — On March 24, World Tuberculosis (TB) Day offers an opportunity to take stock of global progress against the deadliest disease in human history. This year, we face a sobering reality: since the start of the COVID-19 pandemic, rates of TB infection and death are higher than they’ve been since the…

TAG Applauds Price Reduction of Molbio’s Truenat Diagnostics for Tuberculosis
March 17, 2023 — Treatment Action Group (TAG) applauds Molbio’s agreement with the Stop TB Partnership, USAID, and the Global Fund to reduce the price of Truenat diagnostic tests for tuberculosis (TB) from US$9 per test to $7.90 per test and to provide quality service and maintenance of Truenat testing instruments globally.

CROI 2023 Tuberculosis Research Round Up
February 22, 2023 — Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI).

Treatment Action Group Announces Palm Desert Exhibition at Melissa Morgan Fine Art – “35 Years of Art to End AIDS”
February 9, 2023 — Treatment Action Group (TAG) is pleased to present the exhibition “35 Years of Art to End AIDS” at Melissa Morgan Fine Art in Palm Desert, CA. The exhibition features selected works from TAG’s Limited Art Editions Collection and will run from March 17 through April 7.

Community Call to Action on Equitable Access to Long-Acting Therapies
February 1, 2023 — The growing pipeline for long-acting therapies and their potential to accelerate various national and global disease elimination goals warrants global community mobilization to ensure equitable access to these therapies.

Back To Top